MedTrace Logo

Masitinib in Patients With Symptomatic Mild to Moderate COVID-19

NCT05047783 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2023-02-06

No results posted yet for this study

Summary

The objective of the study is to evaluate the anti-viral efficacy of 3 different dosages of masitinib in patients with symptomatic mild to moderate COVID-19.

Conditions

  • Covid19
  • SARS-CoV2 Infection
  • Coronavirus Disease 2019

Interventions

DRUG

Masitinib Mesylate

3CL-protease inhibitor

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Guillaume LAURICHESSE, MD · CHU Gabriel-Montpied, Clermont-Ferrand

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-23
Primary Completion
2023-12-31
Completion
2023-12-31
FDA Drug
Yes

Countries

  • France
  • Russia
  • South Africa

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05047783 on ClinicalTrials.gov